Citations

Clear

213 citation(s) found for "Lloyd, R".

Routine microaxial left ventricular support during nonemergent high-risk PCI: an updated systematic review and meta-analysis with Bayesian and grade methodologies
Mohamed, Ahmed , Abomohsen, Mustafa, Almakadma, Abdul Hakim , Kholeif, Zeyad, Elalfy, Aya, Idries, Iyad, Abdelkhalek, Ahmed M., Elkhayat, Ibrahim , Ghannam, Mohammed, AlQassab, Osamah, Mojahedi, Azad , Gadelmawla, Ahmed Farid, Rashwan, Rana , Farid, Meena, Gunsburg, Moshe, Chadow, Hal L., Abomohsen, Mustafa , Kholeif, Zeyad , Elalfy, Aya, Idries, Iyad Y., Ghannam, Mohammed, Gadelmawla, Ahmed Farid , Rashwan, Rana , Farid, Meena, Gunsburg, Moshe, Chadow, Hal Lloyd

Mayo Clinic

Expert Review of Medical Devices | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1080/17434440.2026.2737101 | PMID 42760266 Get It

Revascularization in Asymptomatic Carotid Artery Stenosis With Hemodynamic Impairment and Cognitive Outcomes
Marshall, Randolph S. , Lazar, Ronald M. , Meschia, James F., Huston, John, Edwards, Lloyd J., Brott, Thomas G., Lal, Brajesh K., Howard, George, Mena-Hurtado, Carlos, Heck, Donald, Sangha, Navdeep, Lanzino, Giuseppe, Kashyap, Vikram S. , Aronow, Herbert D. , Sharafuddin, Mel, Voeks, Jenifer, Slane, Kevin, Liebeskind, David S., Meschia, James F. , Edwards, Lloyd J. , Brott, Thomas G. , Lal, Brajesh K. , Mena‐Hurtado, Carlos , Heck, Donald , Sangha, Navdeep , Lanzino, Giuseppe , Voeks, Jenifer H. , Zhang, Yu , Slane, Kevin, Liebeskind, David S.

Mayo Clinic

JAMA | September 16, 2026 | Volume: 336 | Issue: 16 | Pages: 1416

10.1001/jama.2026.13384 | PMID 42747834 Get It

Importance Cerebral hemodynamic impairment in patients with asymptomatic internal carotid artery (ICA) stenosis is associated with reduced cognition. It is uncertain whether revascularization might be an effective treatment for cognitive impairment in these patients. Objective To test whether any cognitive benefit from revascularization of high-grade, asymptomatic ICA stenosis varies based on the degree of baseline cerebral hemodynamic impairment. Design, Setting, and Participants This substudy was conducted within a multicenter phase 3 randomized clinical trial. Adults (aged 35-86 years) without dementia with eighth-grade education or higher and unilateral asymptomatic ICA stenosis greater than or equal to 70% were enrolled from January 2018 to July 2024 at 61 sites in North America (last follow-up in July 2025). Of 607 participants screened from 2485 in CREST-2, 392 were enrolled. Magnetic resonance or computed tomographic perfusion imaging tested for baseline hemodynamic impairment defined by delayed time-to-peak (TTP) arrival of intravenous contrast in the hemisphere ipsilateral minus contralateral to the stenotic artery. Intervention Carotid revascularization (endarterectomy or stenting) plus intensive medical management (IMM) vs IMM alone. Main Outcomes and Measures The primary outcome was the difference in composite cognitive z score over 1 year based on 5 cognitive tests. The primary analysis tested for an interaction between treatment group (revascularization vs IMM alone) and degree of baseline hemodynamic impairment among those with reduced baseline cognition (cognitive z score ≤−1.0 SD). Results Of 392 participants enrolled (mean age, 71 years; 125 [32%] females), 61 were excluded for missing baseline imaging and 40 for missing cognitive examinations or other covariates, leaving 291 with complete data. Fifty-one had reduced cognition at baseline (25 in the revascularization group and 26 in the IMM alone group). TTP ranged from no interhemispheric TTP delay to a more-than-2-second delay. Mean (SD) cognitive z scores were −1.36 (0.51) at baseline and −1.17 (0.47) at 1 year in the revascularization group and −1.34 (0.83) at baseline and −1.01 (0.97) at 1 year in the IMM alone group. The primary analysis showed no difference in cognition by treatment group over 1 year, adjusting for treatment group × hemodynamic status interaction and other covariates (adjusted difference in cognitive z score, −0.15 SD [95% CI, −0.54 to 0.24]). The interaction was not significant (β estimate = 0.018 [95% CI, −0.025 to 0.061]; P = .40). Conclusions and Relevance In this substudy of a randomized clinical trial, there was no differential effect of revascularization vs IMM alone on cognition over 1 year by cerebral hemodynamic status among those with baseline reduced cognition, suggesting that revascularization does not improve cognitive dysfunction by restoring flow to the brain in chronic asymptomatic carotid stenosis. Trial Registration ClinicalTrials.gov Identifier: NCT03121209
Atrioventricular junction ablation in patients with congenital heart disease: a multicenter study on procedural characteristics and outcomes
Misier, N L Ramdat, Moore, J P, Lloyd, M S, Waldmann, V, Mcleod, C J, Chiriac, A, Ratnasamy, C, Kamp, A, Khairy, P, Cano, O, Ramana, H, Evertz, R, Shivkumar, K, Taverne, Y J H J, Groot, N M S De, Misier, N L Ramdat, Moore, Jeremy P. , Lloyd, Michael S. , Waldmann, Victor , McLeod, Christopher J. , Chiriac, Anca , Ratnasamy, Christopher, Kamp, Anna , Cano, Óscar , Evertz, Reinder , Groot, Natasja M.S. de

Mayo Clinic

Europace | June 25, 2026 | Volume: 28 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euag105.1286 Get It

Abstract Objectives This study aimed to investigate the procedural characteristics, efficacy, and safety of atrioventricular junction (AVJ) ablation for atrial tachyarrythmia (AT) in patients with congenital heart disease (CHD). Background Although AVJ ablation is an established treatment option for intractable AT in the general population, there is no existing data on this treatment in patients with CHD. Methods Data were analyzed from an observational, retrospective, multicenter cohort, initiated jointly by the Pediatric and Congenital Electrophysiology Society and the International Society of Adult Congenital Heart Disease. Eleven centers contributed baseline, procedural and longitudinal data, including vital status, echocardiographic data, QRS duration, and NYHA class. Outcomes were assessed at early (3 months-1 year), and late follow-up (≥2 years) after AVJ ablation. Results A total of 66 patients (46.7 ± 20.2 years) underwent 71 AVJ ablations. In total, 58.5% had moderate or complex CHD, including 17.1% patients with a systemic RV or single ventricular circulation. The cumulative AVJ ablation success rate was 98.5%. An abnormal location of the atrioventricular conduction pathway was successfully targeted in 20.0% of the patients, which was significantly more common in patients with complex CHD compared to moderate or mild CHD (44.4%, 15.8%, and 3.6%, respectively; both P<0.05). Thirty-six patients (54.5%) underwent primary pacemaker implantation as part of the ‘pace and ablate’ strategy; final pacing modes were VVI pacing in 60.9%, and CRT/CSP in 39.1%. The transplant-free survival rates at 2, 5 and 10 years after AVJ ablation were 91.5%, 84.3%, and 69.0%, respectively. The acute and long-term complication rates were 3.0% and 13.6%, respectively. Conclusions AVJ ablation can be successfully performed in CHD patients with a high acute success rate and low complication rate. Anatomical challenges were common, which underscores the need for careful planning and operator experience. Given the acceptable long-term survival, these findings support the consideration of a ‘pace and ablate’ strategy in CHD patients with intractable AT.
Net costs associated with inpatient (IP) administration of step-up dosing (SUD) of bispecific antibodies (bsAbs) among Medicare patients (pts) with relapsed/refractory multiple myeloma (MM).
Joseph, Nisha, Inocencio, Timothy, Heitkamp, Shannon, Delea, Thomas, Bryan, Alexandra, Lloyd, Josie, Ma, Qiufei, Ailawadhi, Sikander, Joseph, Nisha S. , Inocencio, Timothy J. , Delea, Thomas E. , Humblet, Olivier , Ma, Qiufei , Ailawadhi, Sikander

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e19504 Get It

e19504 Background: Initiation of bsAbs requires SUD with close monitoring, typically in IP settings, to mitigate early toxicities. As bsAb use expands, it is crucial to understand the financial viability for administering bsAbs, particularly non–PPS-exempt hospitals paid via a capitated, DRG-based method where costs may exceed payout. We compared net costs and payments for Medicare pts initiating bsAbs in the IP setting at non-PPS-exempt hospitals and explored cost variations for hospital characteristics and adverse events (AEs). Methods: Using Medicare FFS Parts A/B claims (10/25/21–10/20/24), pts ≥65 years with MM, IP bsAb initiation, and 12 mos continuous pre-index coverage were identified. Pts receiving other MM therapies <30 days post-index or treated in PPS-exempt hospitals were excluded. Hospital costs were estimated by applying revenue center–specific Medicare cost–charge ratios from CMS Hospital Cost Reports to IP facility charges. Outpatient (OP) bsAb costs were estimated using ASP/unit administered/wasted at the time of the claim. Costs for other OP services were estimated using revenue center–specific cost–charge ratios. Medicare payments were defined as total allowed amounts on IP and OP claims, and net cost as payments minus estimated costs. IP resource use and net cost recovery by academic vs nonacademic hospital, length of stay (LOS), and AEs were analyzed. Results: Of 3074 pts with a bsAb claim, 1129 met inclusion criteria. Mean IP LOS was 9 days (range 1–68). Hospital mean estimated IP cost/day for index hospitalization was $3963. Mean estimated costs for index hospitalization were $36964 per pt for IP SUD and $28366 for mean Medicare payments with a mean loss of $8598 per pt (median −$5616). Payments exceeded estimated costs on average by $2764–8149 for 1–4-day hospitalizations and roughly equal costs for hospitalizations at 5 days. For pts with LOS of 6–9 days and ≥10 days, payments were lower than costs by $6735 and $16659, respectively, suggesting a loss. For pts with subsequent OP administrations (74%) observable in this sample, cumulative payments and costs were assessed following the index hospitalization, mean cumulative longitudinal payments were ≥ cumulative costs within 2–3 mos. IP stay net losses were higher among pts with infection (−$6406 vs no infection), neutropenia (−$7006), and febrile neutropenia (−$10018). Payment patterns and estimated costs were similar across hospital types. Conclusions: Results suggest a large financial burden on non-PPS-exempt hospitals for IP-administered bsAb SUD. While shorter LOS for IP SUD generally did not result in financial losses, longer LOS was associated with disproportionately higher costs relative to payments. Care models (e.g. OP SUD) are key to manage initiation costs and ensure delivery of care for bsAbs remains financially sustainable.
Crestomics: Analyzing Carotid Plaques in the Crest-2 Trial with a New Additive Classification Model
Kulkarni, Pranav, Lal, Brajesh K., Jreij, Georges , Vallamchetla, Sai, Green, Langford, Voeks, Jenifer, Huston, John , Edwards, Lloyd, Howard, George, Maron, Bradley A. , Brott, Thomas G., Meschia, J, Doo, Florence X., Huang, Heng , Edwards, Lloyd J. , Edwards, Lloyd J. , Lal, Brajesh K. , Voeks, Jenifer H. , Brott, Thomas G. , Meschia, James F. , Doo, Florence Xini

Mayo Clinic

2026 IEEE 23rd International Symposium on Biomedical Imaging (ISBI) | May 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/isbi61048.2026.11515421 Get It

Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic
Patel, Shyam A. , Zhu, Valerie, Gerber, William K , Suzuki, Sakiko , Barker, Charlotte, Hutchinson, Lloyd, Khedr, Salwa, Cachia, David , Mangaonkar, Abhishek A. , McGuiness, Matthew, Higgins, Anne W. , Miron, Patricia M., Gerber, Jonathan M., Patel, Shyam A , Hutchinson, Lloyd, Khedr, Salwa , Miron, Patricia Minehart , Gerber, Jonathan M.

Mayo Clinic

American Journal of Hematology | May 20, 2026 | Volume: 101 | Issue: 8 | Pages: 1915-1927

10.1002/ajh.70374 | PMID 42157378 Get It

ABSTRACT Age‐related changes in human hematopoietic stem cells (HSCs) often form the basis for clonal hematopoiesis (CH), which presages the development of overt myeloid neoplasm with variable risk. CH can also arise after exposure to chemotherapy, radiotherapy, or immune interventions. In this study, we performed clinico‐genomic profiling of therapy‐related CH (t‐CH) ( n = 67) versus de novo CH ( n = 123) from a multidisciplinary CHIP Clinic. The most enriched mutations in t‐CH were TET2 (26.2%), DNMT3A (22.4%), and TP53 (8.4%). Median latency period from the time of initial exposure to the diagnosis of t‐CH was 6.96 ± 1.10 years. Patients with t‐CH had inferior event‐free survival compared to de novo CH (median 29.9 months versus 122.1 months, p = 0.0045). Overall survival was also shorter in t‐CH versus de novo CH (median 55.3 months vs. 129.2 months, p = 0.043). Genes that imparted significantly increased risk for progression from t‐CH to overt therapy‐related myeloid neoplasm (t‐MN) included JAK2 (relative risk (RR) 9.42, p = 0.0001), RUNX1 (RR 7.11, p = 0.001), EZH2 (RR 7.11, p = 0.001), and TET2 (RR 13.4, p = 0.01). Clonal dynamic modeling of patients with t‐CH who progressed to overt t‐MN showed an increase in the relative clonal fraction and new clonal outgrowth. In the t‐CH cohort, higher mean variant allele frequency was observed in progressors versus non‐progressors (77.1% vs. 30.6%, p = 0.017). This study sheds light onto outcomes for CH based on differing clinical ontogeny and has implications for previvorship for secondary malignancies.
Novel BRAF fusion in Erdheim–Chester disease with pulmonary manifestations: Importance of RNA ‐based te
Odintsov, Igor , Tazelaar, Henry D. , Lee, Jerry C. , Damon, Lloyd, Devine, W. Patrick , Jones, Kirk D. , Odintsov, Igor , Damon, Lloyd E , Devine, Walter Patrick , Tazelaar, Henry D.

Mayo Clinic

Histopathology | May 5, 2026 | Volume: 89 | Issue: 3 | Pages: 558-561

10.1111/his.70170 | PMID 42082348 Get It

Abstract 7392: A cancer cell-intrinsic PAR1/MALT1/PD-L1 signaling pathway drives immune evasion in triple-negative breast cancer
Hu, D. C., Ekambaram, Prasanna , Klei, Linda R. , Beecher, Maria , Cai, Zongyou , Little, John R. , Meridew, Jeffrey A., Thompson, E. Aubrey, Covic, Lidija , Lim, Seung-Oe, Ford, Heide L. , Hung, Mien-Chie, Oesterreich, S., McAllister-Lucas, Linda M., Li, Zheqi , Liu, Yi , Little, John, Lee, Jia-Ying Lloyd , Thompson, E. Aubrey , Bruno, Tullia Carmela , Dongre, Anushka , Hung, Mien‐Chie , Lee, Adrian V. , Oesterreich, Steffi , McAllister‐Lucas, Linda M. , Lucas, Peter C.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7392-7392

10.1158/1538-7445.am2026-7392 Get It

Abstract Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and remains difficult to treat due to the absence of targeted therapies. While recent advances in immunotherapy, particularly with immune checkpoint inhibitors (ICIs), have transformed the treatment landscape for many cancers, response rates to ICIs remain low for TNBC, largely due to tumor-intrinsic immune evasion mechanisms. Objective: We identify and characterize a novel immune evasion pathway in TNBC driven by deregulation of cancer cell-intrinsic protease-activated receptor 1 (PAR1), a thrombin receptor frequently upregulated in aggressive tumors. Methods and Results: Through integrative bioinformatic analyses, genetic perturbations, xenograft models (immunodeficient and immunocompetent), flow cytometry-based tumor immune profiling, and RNA-seq, we demonstrate that PAR1 activation enhances immune evasion in TNBC. Mechanistically, we show that the paracaspase MALT1 acts as a critical downstream effector of PAR1 signaling and promotes immune escape by driving PD-L1 expression in TNBC cells. Functional assays reveal that genetic depletion of MALT1 or PD-L1 increases TNBC cell susceptibility to T cell-mediated cytotoxicity in vitro and significantly suppresses tumor growth in vivo. Notably, through knock-in and rescue experiments using a catalytically inactive MALT1 mutant, we reveal that MALT1’s scaffolding - rather than protease - function is essential for PD-L1 regulation. Immune cell depletion assays further identify CD4+ T cells, CD8+ T cells, and natural killer (NK) cells as key mediators of the anti-tumor immune response suppressed by the PAR1-MALT1 axis. These findings are supported by human TNBC specimen analyses, where MALT1 expression inversely correlates with T cell activation and positively associates with PD-L1 in PAR1-high, but not PAR1-low, tumors. Conclusion: Our study reveals immune evasion as a novel mechanism of PAR1-driven breast cancer pathogenesis, mediated by a PAR1/MALT1/PD-L1 signaling cascade. These findings bridge a critical gap by positioning MALT1 at the interface between tumor-intrinsic signaling and the immune microenvironment - two areas of CARMA-BCL10-MALT1 (CBM) complex research that have largely evolved in parallel over the years. Importantly, targeting MALT1 may enhance immunotherapy efficacy in TNBC. Given the availability of MALT1 inhibitors in clinical development, our work supports combining MALT1 inhibition with ICIs or other immune-oncology agents as a promising strategy to overcome immune resistance in TNBC. Citation Format: Dong Hu, Prasanna Ekambaram, Zheqi Li, Linda Klei, Maria L. Beecher, Yi Liu, Zongyou Cai, John Little, Jeffrey A. Meridew, Jia-Ying Lee, E. Aubrey Thompson, Tullia C. Bruno, Lidija Covic, Seung-Oe Lim, Anushka Dongre, Heide L. Ford, Mien-Chie Hung, Adrian V. Lee, Steffi Oesterreich, Linda McAllister-Lucas, Peter C. Lucas. A cancer cell-intrinsic PAR1/MALT1/PD-L1 signaling pathway drives immune evasion in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7392.
Abstract DP131: Impact of Degree of Stenosis on Time-To-Peak Delay in High Grade Asymptomatic Carotid Artery Disease
Huston, John, Edwards, Lloyd J. , Meschia, James F., Lal, Brajesh K. , Brott, T., Howard, George S. , Jumani, Shariq, Mena-Hurtado, Carlos, Heck, Donald A., Sangha, Navdeep, Lanzino, Giuseppe, Sharafuddin, Mel, Lazar, Ronald M. , Liebeskind, D, Edwards, Lloyd J. , Marshall, Randolph S. , Howard, George, Mena‐Hurtado, Carlos , Heck, Donald, Sangha, Navdeep , Lanzino, Giuseppe , Kashyap, Vikram S. , Aronow, Herbert D.

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp131 Get It

Objectives: Cerebral hemodynamic impairment in patients with asymptomatic high-grade internal carotid artery (ICA) stenosis confers a risk of stroke and cognitive decline, but correlations between degree of stenosis and hemodynamic impairment are derived from small case series only. Using baseline data from 282 participants in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis – Hemodynamics (CREST-H) study, we hypothesized that degree of stenosis, measured by peak systolic velocity (PSV) and end diastolic velocity (EDV) in the ipsilateral ICA, would correlate with time-to-peak (TTP) delay using MR (n=275) or CT (n=7) perfusion scans, adjusting for demographic and cardiovascular risk variables. Methods: Using a 7-10MHz Doppler probe, ICA PSV and EDV were assessed. Doppler results were adjudicated centrally. Dynamic contrast perfusion imaging was standardized across 61 CREST-H sites, using sequential T2*-weighted time-sequence scanning (e.g. TR=1500, TE=25ms, flip angle=60deg, phase=128, slice thickness=5mm for GE 3T magnet). CTP was acquired with standard clinical protocols. TTP delay was calculated in the ipsilateral versus contralateral MCA/ACA territories using OLEA software. Linear regression used TTP delay as the outcome variable and PSV and EDV as predictor variables, adjusting for covariates.The 282 with complete data for all variables were included in the analysis. Results: Among 392 CREST-H participants, 63% were men, 7% Black, 3% Hispanic, 33% with less than college education. Tables 1a/b show the regression results for PSV and EDV as main predictor variables. PSV and EDV on the index side significantly correlated with TTP delay (p=0.004, p=0.002 respectively). Neither PSV nor EDV on the non-index side correlated with TTP delay (p=0.49, p=0.82). Compared with moderate exercise, vigorous exercise correlated with lower TTP delay in both models (p=0.05. p=0.04). Compared with college graduates, those with HS education had longer TTP delays in both models (p=0.03. p=0.02). Conclusions: In this large cohort of patients with high-grade asymptomatic carotid stenosis, higher flow velocities correlated with greater TTP delays, suggesting an increasing hemodynamic impairment with greater degree of stenosis above 70%. Our findings have implications for management of asymptomatic carotid stenosis which are being tested in the CREST-H and CREST-2 studies. Exercise and education may independently impact cerebral hemodynamics.